InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025

DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal third quarter ended March 31, 2025. “Our third quarter results reflect continued strength in topline growth, disciplined cost management, and effective medical expense control,” said CEO Patrick Blair. “We are executing with greater consistency, and we are focused on building a PACE platform that delivers better outcomes for participants, generates meaningful savings for the healthcare system, and creates long-term value for our shareholders.” Financial Results Three Months Ended March 31, 2025 2024 in thousands, except percentages and per share amounts Total revenues$218,142 $193,071 Loss Before Income Taxes (11,061) (6,408)Net Loss (11,133) (6,184)Net Loss margin(5.1)% (3.2)% Net Loss Attributable to InnovAge Holding Corp. (11,378) (5,887)Net Loss per share - basic and diluted$(0.08) $(0.04) Center-level Contribution Margin(1)$40,747 $33,997 Adjusted EBITDA(1)$10,792 $2,955 Adjusted EBITDA margin(1) 4.9% 1.5% Fiscal Third Quarter 2025 Financial Performance Total revenue of $218.1 million, increased approximately 13.0% compared to $193.1 million in the third quarter of fiscal year 2024Loss Before Income Taxes of $11.1 million increased approximately 72.6%, compared to a Loss Before Income Taxes of $6.4 million in the third quarter of fiscal year 2024Loss Before Income Taxes as a percent of revenue was 5.1%, an increase of 1.8 percentage points, compared to Loss Before Income Tax as a percent of revenue of 3.3% in the third quarter of fiscal year 2024Center-level Contribution Margin(1) of $40.7 million, increased 19.9% compared to $34.0 million in the third quarter of fiscal year 2024Center-level Contribution Margin(1) as a percent of revenue of 18.7%, increased 1.1 percentage points compared to 17.6% in the third quarter of fiscal year 2024Net loss of $11.1 million, compared to net loss of $6.2 million in the third quarter of fiscal year 2024Net loss margin of 5.1%, an increase of 1.9 percentage points compared to a net loss margin of 3.2% in the third quarter of fiscal year 2024Net loss attributable to InnovAge Holding Corp. of $11.4 million, or a loss of $0.08 per share, compared to net loss of $5.9 million, or a loss of $0.04 per share in the third quarter of fiscal year 2024Adjusted EBITDA(1) of $10.8 million, an increase of $7.8 million compared to Adjusted EBITDA of $3.0 million in the third quarter of fiscal year 2024Adjusted EBITDA(1) margin of 4.9%, an increase of 3.4 percentage points compared to 1.5% in the third quarter of fiscal year 2024Census of approximately 7,530 participants compared to 6,820 participants in the third quarter of fiscal year 2024Ended the third quarter of fiscal year 2025 with $60.5 million in cash and cash equivalents plus $41.3 million in short-term investments, and $77.3 million in debt on the balance sheet, representing debt under the Company’s senior secured term loan, convertible term loan and finance leases (1) Center-level Contribution Margin and Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. Effective for the year ended June 30, 2024 and going forward, the Company revised its calculation of Adjusted EBITDA and has recast the presentation for each of the three and nine months ended March 31, 2024 to conform to the current presentation. For more details and for a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the periods indicated, see “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures.” Dr. Richard Feifer, InnovAge’s Chief Medical Officer, notified the Company of his intent to pursue other opportunities and departed effective April 25, 2025. Full Fiscal Year 2025 Financial Guidance Based on information as of today, May 6, 2025, InnovAge is confirming the following financial guidance. Low High dollars in millionsCensus 7,300 7,750Total Member Months(1) 86,000 89,000 Total revenues$815 $865Adjusted EBITDA(2)$24 $31 Expected results and estimates may be impacted by factors outside the Company’s control especially in light of the highly uncertain and rapidly evolving microeconomic environment and the volatility of the financial and capital markets. Accordingly, actual results may be materially different from this guidance. See “Forward-Looking Statements - Safe Harbor” herein. (1) We define Total Member Months as the total number of participants as of period end multiplied by the number of months within a year in which each participant was enrolled in our program. Management believes this is a useful metric as it more precisely tracks the number of participants the Company serves throughout the year. (2)Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” for a definition of Adjusted EBITDA and a reconciliation to net loss, the most closely comparable GAAP measure. The Company is unable to provide guidance for net loss or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items. Conference Call The Company will host a conference call this afternoon at 5:00 PM Eastern Time. A live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link (registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time. About InnovAge InnovAge is a market leader in managing the care of high-cost, frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care our participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of March 31, 2025, InnovAge served approximately 7,530 participants across 20 centers in six states. https://www.innovage.com. Investor Contact: Ryan Kubotarkubota@innovage.com Media Contact: Lara Hazenfieldlhazenfield@innovage.com Forward-Looking Statements - Safe Harbor This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements include, among others, statements we make regarding quarterly or annual financial guidance; financial outlook, including future revenues and future earnings; the viability of our growth strategy including our ability or expectations to increase the number of participants we serve, to build and/or open de novo centers, or to identify and execute tuck-in acquisitions, joint ventures and strategic partnerships; the expected impact of government policies and the macroeconomic environment; our ability to control costs, mitigate the effects of elevated expenses, expand our payor capabilities, implement clinical value and operational value initiatives and strengthen enterprise functions; our expectations with respect to audits, post-sanction work, legal proceedings and government investigations and actions; relationships and discussions with regulatory agencies; our ability to effectively implement operational excellence as a provider across all our centers; reimbursement and regulatory developments; market developments; new services; integration activities; industry and market opportunity; and the effects of any of the foregoing on our future results of operations or financial conditions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on currently available information and our current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control and may cause our actual results and financial condition to differ materially. Important factors that could cause our actual results and financial condition to differ materially include, among others, the following: (i) the viability of our growth strategy, including our ability to attract new participants and retain existing participants in new and existing centers and our ability to obtain licenses to open de novo centers including in Downey and Bakersfield, California; (ii) the impact on our business from ongoing macroeconomic related challenges, including labor shortages, labor competition and inflation, uncertainty surrounding the stability of economic conditions due to new and proposed tariffs and uncertainty in the global trade environment; (iii) inspections, reviews, audits, and investigations under the federal and state government programs, including any corrective action and adverse findings thereunder; (iv) the impact of state and federal efforts to reduce healthcare spending, including recent proposals to reduce the budget that funds Medicaid and Medicare; (v) legal proceedings, enforcement actions and litigation malpractice and privacy disputes, which are costly to defend; (vi) under our PACE contracts, we assume all of the risk that the cost of providing services will exceed our compensation; (vii) the dependence of our revenues upon a limited number of government payors; (viii) the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants, subjecting us to repayment obligations or penalties; and (ix) the impact on our business of renegotiation, non-renewal or termination of capitation agreements with government payors. Forward-looking statements are based only on information currently available to us and speaks only as of the date on which it is made. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. We advise you to not place undue reliance on forward-looking statements and to review our risk factors and other disclosures included in the reports we file or furnish with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Note Regarding Use of Non-GAAP Financial Measures In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”), the Company is also reporting Center-level Contribution Margin, Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. These non-GAAP measures are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) before income taxes, net income (loss) before income taxes margin, net income (loss) and net income (loss) margin, as applicable, as determined by GAAP. We believe that these non-GAAP measures are appropriate measures of operating performance because the metrics eliminate the impact of certain expenses that, in the case of Adjusted EBITDA, do not relate to our ongoing business performance, allowing us to more effectively evaluate our core operating performance and trends from period to period. We believe that these non-GAAP measures help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net income (loss) before taxes, net income (loss) before taxes margin, net income (loss), and net income (loss) margin. The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. For purpose of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expense or corporate, general and administrative expenses across our centers. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. Our use of the term Adjusted EBITDA varies from others in our industry. We define Adjusted EBITDA as net loss adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, litigation costs and settlement, M&A diligence, transaction and integration, business optimization, electronic medical record (“EMR”) implementation, impairment of right-of-use (“ROU”) asset and construction in progress and loss on minority equity interest. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue. Effective for the year ended June 30, 2024, and going forward, the Company revised its calculation of Adjusted EBITDA to no longer exclude de novo center development costs and to reflect the impact of other investment income. The presentation for the three and nine months ended March 31, 2024 has been recast to conform to the current presentation. For a full reconciliation of Center-level Contribution Margin and Adjusted EBITDA to the most closely comparable GAAP financial measures, please see the attachment to this earnings release. Schedule 1 InnovAgeCONDENSED CONSOLIDATED BALANCE SHEETS(IN THOUSANDS, EXCEPT NUMBER OF SHARES) (UNAUDITED) March 31,2025 June 30,2024Assets Current Assets Cash and cash equivalents$60,454 $56,946 Short-term investments 41,279 45,833 Restricted cash 12 14 Accounts receivable, net of allowance ($— – March 31, 2025 and $6,729 – June 30, 2024) 44,400 48,106 Prepaid expenses 26,714 18,919 Income tax receivable 3,324 3,324 Total current assets 176,183 173,142 Noncurrent Assets Property and equipment, net 177,502 193,022 Operating lease assets 25,229 28,416 Investments 2,645 2,645 Deposits and other 9,001 5,949 Goodwill 142,046 139,949 Other intangible assets, net 4,042 4,538 Total noncurrent assets 360,465 374,519 Total assets$536,648 $547,661 Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued expenses$75,175 $55,459 Reported and estimated claims 61,682 55,404 Due to Medicaid and Medicare 17,321 15,197 Current portion of long-term debt 60,983 3,795 Current portion of finance lease obligations 5,397 4,599 Current portion of operating lease obligations 4,761 4,145 Total current liabilities 225,319 138,599 Noncurrent Liabilities Deferred tax liability, net 7,969 7,460 Finance lease obligations 8,797 12,743 Operating lease obligations 23,685 26,275 Other noncurrent liabilities 1,408 1,298 Long-term debt, net of debt issuance costs 1,765 61,478 Total liabilities 268,943 247,853 Commitments and Contingencies Redeemable Noncontrolling Interests 22,100 22,200 Stockholders’ Equity Common stock, $0.001 par value; 500,000,000 authorized as of March 31, 2025 and June 30, 2024; 136,416,941 issued and 135,078,305 outstanding as of March 31, 2025 and 136,152,858 issued and 136,116,299 outstanding as of June 30, 2024 136 136 Treasury stock at cost, 1,361,159 and 36,559 shares as of March 31, 2025 and June 30, 2024, respectively (7,203) (179)Additional paid-in capital 342,870 337,615 Retained deficit (97,839) (68,311)Total InnovAge Holding Corp. 237,964 269,261 Noncontrolling interests 7,641 8,347 Total stockholders’ equity 245,605 277,608 Total liabilities and stockholders’ equity$536,648 $547,661 Schedule 2 InnovAgeCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA) (UNAUDITED) Three Months Ended March 31, Nine Months Ended March 31, 2025 2024 2025 2024 Revenues Capitation revenue$217,819 $192,756 $631,293 $563,490 Other service revenue 323 315 989 964 Total revenues 218,142 193,071 632,282 564,454 Expenses External provider costs 107,896 99,996 322,983 300,319 Cost of care, excluding depreciation and amortization 69,499 59,078 196,947 168,649 Sales and marketing 6,922 7,179 21,117 18,416 Corporate, general and administrative 38,597 27,549 94,235 81,746 Depreciation and amortization 5,386 5,062 16,116 13,621 Impairment of right-of-use asset and construction in progress — — 8,495 — Total expenses 228,300 198,864 659,893 582,751 Operating Loss (10,158) (5,793) (27,611) (18,297) Other Income (Expense) Interest expense, net (1,160) (1,022) (3,719) (2,619)Other income 257 525 1,489 2,043 Gain (loss) on equity method investment — (118) 16 (2,000)Total other expense (903) (615) (2,214) (2,576)Loss Before Income Taxes (11,061) (6,408) (29,825) (20,873)Provision (Benefit) for Income Taxes 72 (224) 509 94 Net Loss (11,133) (6,184) (30,334) (20,967)Less: net income (loss) attributable to noncontrolling interests 245 (297) (806) (1,329)Net Loss Attributable to InnovAge Holding Corp.$(11,378) $(5,887) $(29,528) $(19,638) Weighted-average number of common shares outstanding - basic 135,200,314 135,908,256 135,471,907 135,861,922 Weighted-average number of common shares outstanding - diluted 135,200,314 135,908,256 135,471,907 135,861,922 Net loss per share - basic$(0.08) $(0.04) $(0.22) $(0.14)Net loss per share - diluted$(0.08) $(0.04) $(0.22) $(0.14) Schedule 3 InnovAgeCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(IN THOUSANDS) (UNAUDITED) For the Nine Months Ended March 31, 2025 2024 Operating Activities Net loss$(30,334) $(20,967)Adjustments to reconcile net loss to net cash provided by (used in) operating activities Loss (gain) on disposal of assets 260 (14)Provision for uncollectible accounts 524 5,252 Depreciation and amortization 16,116 13,621 Operating lease rentals 4,738 3,831 Impairment of right-of-use asset and construction in progress 8,495 — Amortization of deferred financing costs 322 322 Stock-based compensation 6,069 5,140 Loss on minority equity interest investment — 2,000 Deferred income taxes 509 (78)Other, net 1,173 302 Changes in operating assets and liabilities, net of acquisitions Accounts receivable, net 3,183 (16,802)Prepaid expenses and other current assets (6,275) 4,382 Income tax receivable — (3,068)Deposits and other (4,471) (2,350)Accounts payable and accrued expenses 20,062 (5,402)Reported and estimated claims 6,278 6,171 Due to Medicaid and Medicare 2,125 2,270 Income taxes payable — (1,212)Operating lease liabilities (4,909) (4,054)Deferred revenue — (28,115)Net cash provided by (used in) operating activities 23,865 (38,771)Investing Activities Purchases of property and equipment (6,442) (4,609)Purchases of short-term investments (1,610) (1,782)Proceeds from sale of short-term investments 6,300 3,000 Acquisition of business (4,774) (23,916)Net cash used in investing activities (6,526) (27,307)Financing Activities Payments for finance lease obligations (3,147) (3,581)Principal payments on long-term debt (2,848) (2,846)Repurchase of equity securities (7,024) — Taxes paid related to net settlements of stock-based compensation awards (814) (651)Net cash used in financing activities (13,833) (7,078) INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS & RESTRICTED CASH 3,506 (73,156)CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD 56,960 127,265 CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD$60,466 $54,109 Supplemental Cash Flows Information Interest paid$3,413 $2,894 Income taxes paid$1 $4,452 Property and equipment included in accounts payable$52 $432 Property and equipment purchased under finance leases$— $108 Schedule 4 InnovAgeRECONCILIATION OF GAAP AND NON-GAAP MEASURES(IN THOUSANDS) (UNAUDITED) Adjusted EBITDA Three months ended March 31, Nine months ended March 31, 2025 2024 2025 2024 Net loss$(11,133) $(6,184) $(30,334) $(20,967)Interest expense, net 1,160 1,022 3,719 2,619 Other investment income(a) (503) (590) (1,750) (1,788)Depreciation and amortization 5,386 5,062 16,116 13,621 Provision for income tax 72 (224) 509 94 Stock-based compensation 2,035 1,551 6,069 5,140 Litigation costs and settlement(b) 13,277 897 17,741 2,802 M&A diligence, transaction and integration(c) 202 210 1,582 384 Business optimization(d) 152 738 845 3,672 EMR implementation(e) — 355 — 3,659 Asset impairments and loss on sale of assets(f) 144 — 8,639 — Loss on minority equity interest(g) — 118 — 2,000 Adjusted EBITDA$10,792 $2,955 $23,136 $11,236 Net loss margin(6.4)% (2.0)% (4.6)% (4.0)%Adjusted EBITDA margin 2.8% 3.7% 3.0% 2.2% _______________________(a)Reflects investment income related to short-term investments included in our consolidated statement of operations. Effective for the year ended June 30, 2024 and going forward, the Company revised the calculation for Adjusted EBITDA to reflect the impact of investment income. The presentation for the three and nine months ended March 31, 2024 has been recast to reflect the impact of other investment income.(b)Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center, and civil investigative demands. Refer to Note 9, "Commitments and Contingencies" to our condensed consolidated financial statements for more information regarding litigation by stockholders and civil investigative demands. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy. For the three and nine months ended March 31, 2025, includes $10.7 million accrued in connection with the potential settlement of the previously disclosed stockholder class action.(c)Reflects charges related to M&A transaction and integrations. The presentation for the three and nine months ended March 31, 2024 has been recast to no longer exclude de novo center development costs.(d)Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations. For the three months ended March 31, 2025, this primarily includes costs related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the nine months ended March 31, 2025, this includes (i) $0.4 million of costs associated with organizational restructure and (ii) $0.4 million related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the three months ended March 31, 2024, this includes (i) $0.4 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing capabilities, and strengthen our enterprise capabilities and (ii) $0.3 million related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the nine months ended March 31, 2024, this includes (i) $2.6 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing capabilities, and strengthen our enterprise capabilities, (ii) $0.3 million of costs associated with organizational restructure, and (iii) $0.8 million related to other non-recurring projects aimed at reducing costs and improving efficiencies.(e)Reflects non-recurring expenses relating to the implementation of a new EMR vendor.(f)Reflects (i) impairment charges related to ROU asset and construction in progress related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing and (ii) loss on sale of center equipment that was originally purchased for the center in Louisville, Kentucky.(g)Reflects impairment charges related to our minority equity interest in Jetdoc, Inc. Three months endedDecember 31, 2024 Net loss$(13,491)Interest expense, net 760 Other investment income 141 Depreciation and amortization 5,319 Provision for income tax 34 Stock-based compensation 1,873 Litigation costs and settlement(a) 1,405 M&A diligence, transaction and integration 1,275 Business optimization(b) 58 Impairment of right-of-use asset and construction in progress(c) 8,495 Adjusted EBITDA$5,869 Net loss margin(5.1)%Adjusted EBITDA margin 4.9% _______________________(a)Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center, and civil investigative demands. Refer to Note 9, “Commitments and Contingencies” to our condensed consolidated financial statements contained in our Quarterly Report on Form 10-Q for more information regarding litigation by stockholders and civil investigative demands. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy.(b)Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations. For the three months ended December 31, 2024, this primarily includes costs related to other non-recurring projects aimed at reducing costs and improving efficiencies.(c)Reflects impairment charges related to ROU asset and construction in progress related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing. Center-Level Contribution Margin Three Months Ended March 31, 2025 Three Months Ended March 31, 2024(In thousands)PACE All other(a) Totals PACE All other(a) TotalsCapitation revenue$217,819 $— $217,819 $192,756 $— $192,756 Other service revenue 79 244 323 78 237 315 Total revenues 217,898 244 218,142 192,834 237 193,071 External provider costs 107,896 — 107,896 99,996 — 99,996 Cost of care, excluding depreciation and amortization 69,372 127 69,499 58,959 119 59,078 Center-Level Contribution Margin 40,630 117 40,747 33,879 118 33,997 Overhead costs(b) 45,519 — 45,519 34,727 1 34,728 Depreciation and amortization 5,279 107 5,386 4,929 133 5,062 Interest expense, net (1,117) (43) (1,160) (978) (44) (1,022)Other income 257 — 257 525 — 525 Gain (loss) on equity method investment — — — (118) — (118)Loss Before Income Taxes$(11,028) $(33) $(11,061) $(6,348) $(60) $(6,408)Loss Before Income Taxes as a % of revenue (5.1)% (3.3)%Center- Level Contribution Margin as a % of revenue 18.7% 17.6% December 31, 2024(In thousands)PACE All other(a) TotalsCapitation revenue$208,674 $— $208,674 Other service revenue 77 248 325 Total revenues 208,751 248 208,999 External provider costs 107,873 — 107,873 Cost of care, excluding depreciation and amortization 63,916 145 64,061 Center-Level Contribution Margin 36,962 103 37,065 Overhead costs(b) 35,807 — 35,807 Depreciation and amortization 5,204 115 5,319 Impairment of right-of-use asset and construction in progress 8,495 — 8,495 Interest expense, net (716) (44) (760)Other income (expense) (157) — (157)Gain (loss) on equity method investment 16 — 16 Loss Before Income Taxes$(13,401) $(56) $(13,457)Loss Before Income Taxes as a % of revenue (6.4)%Center- Level Contribution Margin as a % of revenue 17.7% _______________________(a)Center-level Contribution Margin from segments below the quantitative thresholds are primarily attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.(b)Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items. This press release was published by a CLEAR® Verified individual.

InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025

FAQ

Why Neutral?

How important is it?

Why Short Term?

Related Companies

Related News